

Samuel Dagogo-Jack

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/152487/publications.pdf>

Version: 2024-02-01

131
papers

8,861
citations

108046

37
h-index

49824

91
g-index

131
all docs

131
docs citations

131
times ranked

10381
citing authors

#	ARTICLE	IF	CITATIONS
1	Racial and ethnic disparities associated with the measure for drug-drug interactions among Medicare beneficiaries. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2022, 62, 142-149.	0.7	1
2	Severe Hypoglycemia and Incident Heart Failure Among Adults With Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e955-e962.	1.8	17
3	DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases. <i>Journal of Diabetes and Its Complications</i> , 2022, 36, 108101.	1.2	23
4	Plasma FGF-21 and Sclerostin Levels, Glycemia, Adiposity, and Insulin Sensitivity in Normoglycemic Black and White Adults. <i>Journal of the Endocrine Society</i> , 2022, 6, bvab183.	0.1	3
5	Cardiorenal outcomes with ertugliflozin assessed according to baseline glucose-lowering agent: An analysis from <scp>VERTIS CV</scp>. <i>Diabetes, Obesity and Metabolism</i> , 2022, , .	2.2	5
6	Outcome of lifestyle intervention in relation to duration of pre-diabetes: the Pathobiology and Reversibility of Prediabetes in a Biracial Cohort (PROP-ABC) study. <i>BMJ Open Diabetes Research and Care</i> , 2022, 10, e002748.	1.2	6
7	Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes mellitus. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1829-1839.	2.2	23
8	Role of ceramides in the pathogenesis of diabetes mellitus and its complications. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 107734.	1.2	48
9	Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes. <i>JAMA Cardiology</i> , 2021, 6, 148.	3.0	625
10	Gradient of Risk and Associations With Cardiovascular Efficacy of Ertugliflozin by Measures of Kidney Function. <i>Circulation</i> , 2021, 143, 602-605.	1.6	24
11	Risk Factors for Longitudinal Resting Heart Rate and Its Associations With Cardiovascular Outcomes in the DCCT/EDIC Study. <i>Diabetes Care</i> , 2021, 44, 1125-1132.	4.3	6
12	Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial. <i>Diabetologia</i> , 2021, 64, 1256-1267.	2.9	103
13	Predictive utilities of lipid traits, lipoprotein subfractions and other risk factors for incident diabetes: a machine learning approach in the Diabetes Prevention Program. <i>BMJ Open Diabetes Research and Care</i> , 2021, 9, e001953.	1.2	7
14	Genetic Risk Factors for CVD in Type 1 Diabetes: The DCCT/EDIC Study. <i>Diabetes Care</i> , 2021, 44, 1309-1316.	4.3	4
15	Association of plasma acylcarnitines with insulin sensitivity, insulin secretion, and prediabetes in a biracial cohort. <i>Experimental Biology and Medicine</i> , 2021, 246, 1698-1705.	1.1	4
16	Kidney outcomes using a sustained $\geq 40\%$ decline in <scp>eGFR</scp>: A meta-analysis of <scp>SGLT2</scp> inhibitor trials. <i>Clinical Cardiology</i> , 2021, 44, 1139-1143.	0.7	20
17	Ertugliflozin and Slope of Chronic eGFR. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 1345-1354.	2.2	26
18	Racial/ethnic disparities in measure calculations for Part D Star Ratings among Medicare beneficiaries with diabetes, hypertension, and/or hyperlipidemia. <i>Research in Social and Administrative Pharmacy</i> , 2021, 17, 1469-1477.	1.5	8

#	ARTICLE	IF	CITATIONS
19	Cardiovascular outcomes of antidiabetes medications by race/ethnicity: A systematic review and meta-analysis. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 107980.	1.2	3
20	Exploring racial and ethnic disparities in medication adherence among Medicare comprehensive medication review recipients. <i>Exploratory Research in Clinical and Social Pharmacy</i> , 2021, 3, 100041.	0.6	2
21	Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized trial. <i>BMJ Open Diabetes Research and Care</i> , 2021, 9, e002484.	1.2	14
22	Trajectories of Body Weight and Fat Mass in Relation to Incident Prediabetes in a Biracial Cohort of Free-Living Adults. <i>Journal of the Endocrine Society</i> , 2021, 5, bvaa164.	0.1	5
23	Islet cell encapsulation – Application in diabetes treatment. <i>Experimental Biology and Medicine</i> , 2021, 246, 2570-2578.	1.1	10
24	Association of history of heart failure with hospital outcomes of hyperglycemic crises: Analysis from a University hospital and national cohort. <i>Journal of Diabetes and Its Complications</i> , 2020, 34, 107466.	1.2	5
25	Efficacy of Ertugliflozin on Heart Failure–Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease. <i>Circulation</i> , 2020, 142, 2205-2215.	1.6	156
26	Long-term metformin adherence in the Diabetes Prevention Program Outcomes Study. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e001537.	1.2	14
27	Five-Year Glycemic Trajectories Among Healthy African-American and European-American Offspring of Parents With Type 2 Diabetes. <i>American Journal of the Medical Sciences</i> , 2020, 359, 266-270.	0.4	2
28	Calorie Restriction and Intermittent Fasting: Impact on Glycemic Control in People With Diabetes. <i>Diabetes Spectrum</i> , 2020, 33, 143-148.	0.4	4
29	Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2020, 383, 1425-1435.	13.9	927
30	Regression from prediabetes to normal glucose regulation: State of the science. <i>Experimental Biology and Medicine</i> , 2020, 245, 889-896.	1.1	29
31	Multi-year reproducibility of hyperinsulinemic euglycemic clamp-derived insulin sensitivity in free-living adults: Association with incident prediabetes in the POP-ABC study. <i>Metabolism: Clinical and Experimental</i> , 2020, 109, 154263.	1.5	9
32	Pathobiology and Reversibility of Prediabetes in a Biracial Cohort (PROP-ABC) Study: design of lifestyle intervention. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e000899.	1.2	3
33	Role of the HPA Axis in the Metabolic and Baroreflex Components of Hypoglycemia-Associated Autonomic Failure. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e3466-e3468.	1.8	0
34	Glycemic Response to Oral Dexamethasone Predicts Incident Prediabetes in Normoglycemic Subjects With Parental Diabetes. <i>Journal of the Endocrine Society</i> , 2020, 4, bvaa137.	0.1	1
35	Genetic ancestry markers and difference in A1c between African-American and White in the Diabetes Prevention Program. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 328-336.	1.8	12
36	Regression From Prediabetes to Normal Glucose Regulation and Prevalence of Microvascular Disease in the Diabetes Prevention Program Outcomes Study (DPPOS). <i>Diabetes Care</i> , 2019, 42, 1809-1815.	4.3	61

#	ARTICLE	IF	CITATIONS
37	Biomarkers of insulin action during single soccer sessions before and after a 12-week training period in type 2 diabetes patients on a caloric-restricted diet. <i>Physiology and Behavior</i> , 2019, 209, 112618.	1.0	12
38	Metabolite Profiles of Incident Diabetes and Heterogeneity of Treatment Effect in the Diabetes Prevention Program. <i>Diabetes</i> , 2019, 68, 2337-2349.	0.3	22
39	A Polygenic Lipodystrophy Genetic Risk Score Characterizes Risk Independent of BMI in the Diabetes Prevention Program. <i>Journal of the Endocrine Society</i> , 2019, 3, 1663-1677.	0.1	13
40	Comparative Effectiveness of Medication Therapy Management Eligibility Criteria Across Racial/Ethnic Groups. <i>Journal of the American Geriatrics Society</i> , 2019, 67, 581-587.	1.3	3
41	Prevention begets prevention – lessons from the Da Qing Study. <i>Nature Reviews Endocrinology</i> , 2019, 15, 442-443.	4.3	5
42	Amino acid signature predictive of incident prediabetes: A case-control study nested within the longitudinal pathobiology of prediabetes in a biracial cohort. <i>Metabolism: Clinical and Experimental</i> , 2019, 98, 76-83.	1.5	27
43	Ethnic Disparities in Adiposity: Focus on Non-alcoholic Fatty Liver Disease, Visceral, and Generalized Obesity. <i>Current Obesity Reports</i> , 2019, 8, 243-254.	3.5	37
44	Long-term Effects of Metformin on Diabetes Prevention: Identification of Subgroups That Benefited Most in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study. <i>Diabetes Care</i> , 2019, 42, 601-608.	4.3	82
45	Association of Insulin Dose, Cardiometabolic Risk Factors, and Cardiovascular Disease in Type 1 Diabetes During 30 Years of Follow-up in the DCCT/EDIC Study. <i>Diabetes Care</i> , 2019, 42, 657-664.	4.3	32
46	Response to Comment on Braffett et al. Association of Insulin Dose, Cardiometabolic Risk Factors, and Cardiovascular Disease in Type 1 Diabetes During 30 Years of Follow-up in the DCCT/EDIC Study. <i>Diabetes Care</i> 2019;42:657-664. <i>Diabetes Care</i> , 2019, 42, e137-e137.	4.3	0
47	Sickle Cell Trait, European Ancestry, and Longitudinal Tracking of HbA1c Among African Americans: The Jackson Heart Study. <i>Diabetes Care</i> , 2019, 42, e166-e167.	4.3	2
48	Awareness of Prediabetes Status and Subsequent Health Behavior, Body Weight, and Blood Glucose Levels. <i>Journal of the American Board of Family Medicine</i> , 2019, 32, 20-27.	0.8	17
49	Prediabetes and Cardiovascular Disease. <i>Endocrinology and Metabolism Clinics of North America</i> , 2018, 47, 33-50.	1.2	157
50	Diabetes Care in Nigeria. <i>Annals of Global Health</i> , 2018, 81, 821.	0.8	48
51	Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 530-540.	2.2	121
52	Predictive value positive of MTM eligibility criteria under MMA and ACA in identifying individuals with medication utilization issues. <i>Journal of Pharmaceutical Health Services Research</i> , 2018, 9, 393-401.	0.3	1
53	Physiology of Glycemic Recovery and Stabilization After Hyperinsulinemic Euglycemic Clamp in Healthy Subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 4155-4162.	1.8	9
54	Higher Predictive Value Positive for MMA Than ACA MTM Eligibility Criteria Among Racial and Ethnic Minorities: An Observational Study. <i>Inquiry (United States)</i> , 2018, 55, 004695801879574.	0.5	1

#	ARTICLE	IF	CITATIONS
55	Racial and Ethnic Disparities in Meeting MTM Eligibility Criteria Based on Star Ratings Compared with the Medicare Modernization Act. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2018, 24, 97-107.	0.5	6
56	Design and baseline characteristics of the eValuation of ERTugliflozin efficacy and Safety CardioVascular outcomes trial (VERTIS-CV). <i>American Heart Journal</i> , 2018, 206, 11-23.	1.2	171
57	Parental History of Type 2 Diabetes Abrogates Ethnic Disparities in Key Glucoregulatory Indices. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 514-522.	1.8	4
58	Parental history of type 2 diabetes is associated with lower resting energy expenditure in normoglycemic subjects. <i>BMJ Open Diabetes Research and Care</i> , 2018, 6, e000511.	1.2	7
59	Basal and Dynamic Leptin Secretion: Association with Cardiometabolic Risk and Body Weight Trajectories in African-Americans and European-Americans. <i>Frontiers in Endocrinology</i> , 2018, 9, 12.	1.5	3
60	Ethnic Disparities in Endothelial Function and Its Cardiometabolic Correlates: The Pathobiology of Prediabetes in A Biracial Cohort Study. <i>Frontiers in Endocrinology</i> , 2018, 9, 94.	1.5	8
61	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm â€” 2018 Executive Summary. <i>Endocrine Practice</i> , 2018, 24, 91-121.	1.1	388
62	Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 721-728.	2.2	113
63	Primary Prevention of Type 2 Diabetes: An Imperative for Developing Countries. , 2017, , 7-31.		3
64	Editorial: The continuum of dysglycemia: Predicting progression from prediabetes to type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 1249-1251.	1.2	1
65	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive type 2 Diabetes Management Algorithm â€” 2017 Executive Summary. <i>Endocrine Practice</i> , 2017, 23, 207-238.	1.1	362
66	Relationships between blood pressure and blood glucose among offspring of parents with type 2 diabetes: Prediction of incident dysglycemia in a biracial cohort. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 1580-1586.	1.2	8
67	Insulin-sensitive and insulin-resistant obese and non-obese phenotypes: role in prediction of incident pre-diabetes in a longitudinal biracial cohort. <i>BMJ Open Diabetes Research and Care</i> , 2017, 5, e000415.	1.2	52
68	Hyperglycemic, high anion-gap metabolic acidosis in patients receiving SGLT-2 inhibitors for diabetes management. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 611-614.	1.2	15
69	2015 Presidential Address: 75 Years of Battling Diabetesâ€™Our Global Challenge. <i>Diabetes Care</i> , 2016, 39, 3-9.	4.3	15
70	American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on the Association of SGLT-2 Inhibitors and Diabetic Ketoacidosis. <i>Endocrine Practice</i> , 2016, 22, 753-762.	1.1	242
71	Adiponectin levels predict prediabetes risk: the Pathobiology of Prediabetes in A Biracial Cohort (POP-ABC) study. <i>BMJ Open Diabetes Research and Care</i> , 2016, 4, e000194.	1.2	53
72	Plasma lipid levels predict dysglycemia in a biracial cohort of nondiabetic subjects: Potential mechanisms. <i>Experimental Biology and Medicine</i> , 2016, 241, 1961-1967.	1.1	20

#	ARTICLE	IF	CITATIONS
73	Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease. <i>Diabetes Care</i> , 2016, 39, 1684-1692.	4.3	60
74	Prediabetes as a toxic environment for the initiation of microvascular and macrovascular complications. <i>Experimental Biology and Medicine</i> , 2016, 241, 1323-1331.	1.1	111
75	American Association Of Clinical Endocrinologists And American College Of Endocrinology -Clinical Practice Guidelines For Developing A Diabetes Mellitus Comprehensive Care Plan “ 2015. <i>Endocrine Practice</i> , 2015, 21, 1-87.	1.1	443
76	American Association of Clinical Endocrinologists and American College of Endocrinology “ Clinical Practice Guidelines for Developing A Diabetes Mellitus Comprehensive Care Plan “ 2015 “ Executive Summary. <i>Endocrine Practice</i> , 2015, 21, 413-437.	1.1	359
77	Potential Health Implications of Medication Therapy Management Eligibility Criteria in the Patient Protection and Affordable Care Act Across Racial and Ethnic Groups. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2015, 21, 993-1003.	0.5	9
78	Dietary habits and leisure-time physical activity in relation to adiposity, dyslipidemia, and incident dysglycemia in the pathobiology of prediabetes in a biracial cohort study. <i>Metabolism: Clinical and Experimental</i> , 2015, 64, 1060-1067.	1.5	27
79	Philip E. Cryer, MD: Seminal Contributions to the Understanding of Hypoglycemia and Glucose Counterregulation and the Discovery of HAAF (Cryer Syndrome). <i>Diabetes Care</i> , 2015, 38, 2193-2199.	4.3	23
80	Lack of Racial Disparity in Incident Prediabetes and Glycemic Progression Among Black and White Offspring of Parents With Type 2 Diabetes: The Pathobiology of Prediabetes in a Biracial Cohort (POP-ABC) Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E1078-E1087.	1.8	45
81	Potential effects of racial and ethnic disparities in meeting Medicare medication therapy management eligibility criteria. <i>Journal of Pharmaceutical Health Services Research</i> , 2014, 5, 109-118.	0.3	5
82	Glucoregulatory function among African Americans and European Americans with normal or pre-diabetic hemoglobin A1c levels. <i>Metabolism: Clinical and Experimental</i> , 2014, 63, 767-772.	1.5	13
83	Potential health implications of racial and ethnic disparities in meeting MTM eligibility criteria. <i>Research in Social and Administrative Pharmacy</i> , 2014, 10, 106-125.	1.5	9
84	Effects of medicare part d on disparity implications of medication therapy management eligibility criteria. <i>American Health and Drug Benefits</i> , 2014, 7, 346-58.	0.5	4
85	Recruitment strategies and yields for the Pathobiology of Prediabetes in a Biracial Cohort: a prospective natural history study of incident dysglycemia. <i>BMC Medical Research Methodology</i> , 2013, 13, 64.	1.4	17
86	Hypoglycemia in Patients with Type 1 Diabetes: Epidemiology, Pathogenesis, and Prevention. <i>Current Diabetes Reports</i> , 2013, 13, 669-678.	1.7	43
87	Pathobiology of Prediabetes in a Biracial Cohort (POP-ABC) Study: Baseline Characteristics of Enrolled Subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 120-128.	1.8	27
88	Pathobiology of Prediabetes in a Biracial Cohort (POP-ABC): Retention Strategies. <i>Diabetes Care</i> , 2013, 36, e50-e51.	4.3	1
89	Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society. <i>Diabetes Care</i> , 2013, 36, 1384-1395.	4.3	1,125
90	Disparity implications of the Medicare medication therapy management eligibility criteria: a literature review. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2013, 13, 201-216.	0.7	9

#	ARTICLE	IF	CITATIONS
91	Comment on: Maruthur et al. Does Genetic Ancestry Explain Higher Values of Glycated Hemoglobin in African Americans? <i>Diabetes</i> 2011;60:2434-2438. <i>Diabetes</i> , 2012, 61, e1-e1.	0.3	1
92	Metabolomic Prediction of Diabetes and Cardiovascular Risk. <i>Medical Principles and Practice</i> , 2012, 21, 401-403.	1.1	10
93	Predicting Diabetes: Our Relentless Quest for Genomic Nuggets. <i>Diabetes Care</i> , 2012, 35, 193-195.	4.3	13
94	Ethnic Disparity in Hemoglobin A1c Levels Among Normoglycemic Offspring of Parents with Type 2 Diabetes Mellitus. <i>Endocrine Practice</i> , 2012, 18, 356-362.	1.1	23
95	Preventing diabetes mellitus in developing countries. <i>Nature Reviews Endocrinology</i> , 2012, 8, 557-562.	4.3	34
96	Leukocyte count and cardiometabolic risk among healthy participants with parental type 2 diabetes: the Pathobiology of Prediabetes in a Biracial Cohort study. <i>Ethnicity and Disease</i> , 2012, 22, 445-50.	1.0	7
97	American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for Developing a Diabetes Mellitus Comprehensive Care Plan. <i>Endocrine Practice</i> , 2011, 17, 1-53.	1.1	387
98	Pitfalls in the use of HbA1c as a diagnostic test. <i>Nature Reviews Endocrinology</i> , 2011, 7, 1-1.	4.3	2
99	Five Ms of adherence. <i>Journal of Diabetes</i> , 2011, 3, 169-171.	0.8	10
100	Comorbidities of Diabetes and Hypertension: Mechanisms and Approach to Target Organ Protection. <i>Journal of Clinical Hypertension</i> , 2011, 13, 244-251.	1.0	333
101	Dissociation Between Cardiovascular Risk Markers and Clinical Outcomes in African Americans: Need for Greater Mechanistic Insight. <i>Current Cardiovascular Risk Reports</i> , 2011, 5, 200-206.	0.8	4
102	Prediabetes as a Therapeutic Target. <i>Clinical Chemistry</i> , 2011, 57, 215-220.	1.5	37
103	TCF7L2 Polymorphism, Weight Loss and Proinsulin/Insulin Ratio in the Diabetes Prevention Program. <i>PLoS ONE</i> , 2011, 6, e21518.	1.1	27
104	Pathobiology of Prediabetes in a Biracial Cohort (POP-ABC): design and methods. <i>Ethnicity and Disease</i> , 2011, 21, 33-9.	1.0	27
105	Disparity Implications of Medicare Eligibility Criteria for Medication Therapy Management Services. <i>Health Services Research</i> , 2010, 45, 1061-1082.	1.0	36
106	Principles and Practice of Nonpharmacological Interventions to Reduce Cardiometabolic Risk. <i>Medical Principles and Practice</i> , 2010, 19, 167-175.	1.1	49
107	Pitfalls in the use of HbA1c as a diagnostic test: the ethnic conundrum. <i>Nature Reviews Endocrinology</i> , 2010, 6, 589-593.	4.3	110
108	Fasting Plasma Leptin Level Is a Surrogate Measure of Insulin Sensitivity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 3836-3843.	1.8	43

#	ARTICLE	IF	CITATIONS
109	The role of antipsychotic agents in the development of diabetes mellitus. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2009, 5, 22-23.	2.9	1
110	Glucoregulatory Physiology in Subjects with Low-Normal, High-Normal, or Impaired Fasting Glucose. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 2031-2036.	1.8	28
111	Dynamic Responses to Leptin Secretagogues in Lean, Obese, and Massively Obese Men and Women. <i>Hormone Research</i> , 2008, 70, 174-181.	1.8	6
112	Sex Differences in Diabetes Risk and the Effect of Intensive Lifestyle Modification in the Diabetes Prevention Program. <i>Diabetes Care</i> , 2008, 31, 1416-1421.	4.3	104
113	Understanding and Identifying Pre-diabetes “Can We Halt the Diabetes Epidemic?”. <i>European Endocrinology</i> , 2008, 4, 16.	0.8	3
114	Barriers to Achieving Optimal Glycemic Control in a Multi-Ethnic Society: A US Focus. <i>Current Diabetes Reviews</i> , 2006, 2, 285-293.	0.6	18
115	Primary prevention of type-2 diabetes in developing countries. <i>Journal of the National Medical Association</i> , 2006, 98, 415-9.	0.6	29
116	Primary Prevention of Cardiovascular Disease in Pre-Diabetes: The glass is half full and half empty. <i>Diabetes Care</i> , 2005, 28, 971-972.	4.3	15
117	Inhibition of Cortisol Biosynthesis Decreases Circulating Leptin Levels in Obese Humans. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 5333-5335.	1.8	29
118	Epidemiology of Type 2 Diabetes: Focus on Ethnic Minorities. <i>Medical Clinics of North America</i> , 2005, 89, 949-975.	1.1	114
119	Hypoglycemia in Type 1 Diabetes Mellitus. <i>Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders</i> , 2004, 3, 91-103.	1.8	35
120	Leptin Response to Glucocorticoid Occurs at Physiological Doses and Is Abolished by Fasting. <i>Obesity</i> , 2003, 11, 232-237.	4.0	24
121	Ethnic disparities in type 2 diabetes: pathophysiology and implications for prevention and management. <i>Journal of the National Medical Association</i> , 2003, 95, 774, 779-89.	0.6	44
122	Preventing diabetes-related morbidity and mortality in the primary care setting. <i>Journal of the National Medical Association</i> , 2002, 94, 549-60.	0.6	25
123	Thyroid Function during Pregnancy. <i>Clinical Chemistry</i> , 1999, 45, 2250-2258.	1.5	133
124	Reproducibility of Fasting Plasma Leptin Concentration in Lean and Obese Humans. <i>Endocrine Research</i> , 1999, 25, 1-10.	0.6	17
125	Basal and Stimulated Plasma Leptin in Diabetic Subjects. <i>Obesity</i> , 1999, 7, 537-544.	4.0	17
126	Hyperleptinemia in Patients with End-Stage Renal Disease Undergoing Continuous Ambulatory Peritoneal Dialysis. <i>Peritoneal Dialysis International</i> , 1998, 18, 34-40.	1.1	54

#	ARTICLE	IF	CITATIONS
127	Increased Plasma Leptin Concentration in End-Stage Renal Disease ¹ . Journal of Clinical Endocrinology and Metabolism, 1997, 82, 847-850.	1.8	190
128	Robust Leptin Secretary Responses to Dexamethasone in Obese Subjects*. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 3230-3233.	1.8	123
129	Pathophysiology of Type 2 Diabetes and Modes of Action of Therapeutic Interventions. Archives of Internal Medicine, 1997, 157, 1802.	4.3	71
130	Cerebral transport and metabolism of 1-11C-D-glucose during stepped hypoglycemia. Annals of Neurology, 1995, 38, 599-609.	2.8	23
131	Increased Salivary Concentration of Human Epidermal Growth Factor in Patients Undergoing CAPD. Peritoneal Dialysis International, 1991, 11, 270-273.	1.1	5